Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon’s breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to injections ...

GLP-1 drugs, which stands for glucagon-like peptide ... with the program selling oral weight-loss medications for about $79 ...

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor ... trials of an oral formulation of ...

Some analysts have predicted Rybelsus could eventually become a $5 billion product, once clinicians become accustomed to having an oral alternative to the current injectable GLP-1 drugs.

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

With weight loss drugs like metformin and Ozempic gaining popularity, it's essential to understand how they compare. So we ...